FibroTest/FibroSure Scientific Publications

1162 NAFLD Diagnostic performance of FibroTest, SteatoTest, and ActiTest in patients with NAFLD using the SAF-score as histological reference M Munteanu, D Tiniakos, Q Anstee, F Charlotte, G Marchesini, E Bugianesi, MH. Trauner, CP. Oliveira, C Day, JF Dufour, S Bellentani, Y Ngo, S Traussnigg, P Bedossa, V Ratziu, T Poynard. The study aimed to improve the validation of three blood tests used in NAFLD patients as surrogate markers, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. A total of 600 NAFLD patients with biopsy (blindly assessed using the new SAF score) and blood tests (FibroMax panel) were included from a single-center cohort (FibroFrance) and from the multicenter FLIP consortium. The median NonBinROCs (95% CI) of tests were all significant (P<0.0001) for all stages and grades. None of the other fibrosis tests (NAFLD Fibrosis Score, BARD score and FIB4 score) had such significant increase between each fibrosis stages as FibroTest had. In conclusion, in patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that may offer an alternative to biopsy and correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity, and fibrosis. AA SL D 20 16 BioPredictive S.A. 218 Bd Saint-Germain 75007 PARIS FRANCE Tel : +33 1 45 44 30 64 [email protected] Find all the scientific publications of BioPredictive non-invasive tests on the website : library.biopredictive.com Bio Predictive FibroTest/FibroSure Scientific Publications Oral Communications and Posters for AASLD 2016